A healthcare policy change passed in France is likely to see the country quickly targeted by medicinal cannabis companies with Little Green Pharma (ASX: LGP) quick to confirm their plans to increase product distribution to the country thanks to newly favourable healthcare legislation. The recent amendment to the Projet de loi de financement de la
Read More
Over the years, the Australian cannabis market has consistently posted revenue growth and is expected to be valued at $1.1 billion by 2028. Both Aussies and Europeans are big consumers of cannabis, making them attractive markets for medical cannabis companies like Little Green Pharma (ASX: LGP). Little Green Pharma posted a 37% revenue spike to
Read More
After witnessing a cash burn of $368k in the previous quarter, Cannabis-based pharmaceutical company Althea Group (ASX: AGH) has entered cash flow positivity from its operating activities in Q1 FY24, resulting in a net cash inflow of $35,000. This achievement can be attributed to the Company’s successful cost-cutting initiatives, which have begun to yield results.
Read More
Once again, medical cannabis producer Vitura Health (ASX: VIT) has become the only ASX-listed company operating in the medicinal cannabis space to both generate a profit and declare a dividend since its ASX initiation in 2019. The Company will pay a dividend to shareholders in respect of FY23. The Dividend, which will be paid at
Read More
Australia has made a groundbreaking decision by becoming the first country to legalise the clinical prescribing of MDMA (ecstasy) and psilocybin (magic mushrooms) for the treatment of specific mental health disorders, including PTSD and treatment-resistant depression. Setting Australia apart as the pioneer in adopting psychoactive-based treatments for mental health, as of 1 July, authorised psychiatrists
Read More
The medicinal cannabis industry in Australia has been rapidly gaining momentum, reaching an estimated value of approximately $245 million in 2022 and is projected to maintain a strong CAGR of 16.71% from 2023 to 2027. While the availability of cannabis for general use remains restricted in Australia, the nation continues to attract cannabis manufacturing companies
Read More